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Abstract
Background: The distinction between primary and secondary ovarian tumors may be challenging for pathologists. 
The purpose of the present work was to develop genomic and transcriptomic tools to further refine the pathological 
diagnosis of ovarian tumors after a previous history of breast cancer.
Methods: Sixteen paired breast-ovary tumors from patients with a former diagnosis of breast cancer were collected. 
The genomic profiles of paired tumors were analyzed using the Affymetrix GeneChip® Mapping 50 K Xba Array or 
Genome-Wide Human SNP Array 6.0 (for one pair), and the data were normalized with ITALICS (ITerative and Alternative 
normaLIzation and Copy number calling for affymetrix Snp arrays) algorithm or Partek Genomic Suite, respectively. The 
transcriptome of paired samples was analyzed using Affymetrix GeneChip® Human Genome U133 Plus 2.0 Arrays, and 
the data were normalized with gc-Robust Multi-array Average (gcRMA) algorithm. A hierarchical clustering of these 
samples was performed, combined with a dataset of well-identified primary and secondary ovarian tumors.
Results: In 12 of the 16 paired tumors analyzed, the comparison of genomic profiles confirmed the pathological 
diagnosis of primary ovarian tumor (n = 5) or metastasis of breast cancer (n = 7). Among four cases with uncertain 
pathological diagnosis, genomic profiles were clearly distinct between the ovarian and breast tumors in two pairs, thus 
indicating primary ovarian carcinomas, and showed common patterns in the two others, indicating metastases from 
breast cancer. In all pairs, the result of the transcriptomic analysis was concordant with that of the genomic analysis.
Conclusions: In patients with ovarian carcinoma and a previous history of breast cancer, SNP array analysis can be 
used to distinguish primary and secondary ovarian tumors. Transcriptomic analysis may be used when primary breast 
tissue specimen is not available.
Background
Malignant ovarian tumors comprise a wide and heteroge-
neous collection of primary and secondary tumors. In
patients who had previously developed a breast cancer,
the differential diagnosis between primary ovarian carci-
noma and metastases from breast cancer may be some-
times challenging, while it is mandatory to ensure the
optimal care for patients. Indeed, metastatic spread and
biological pattern differ between metastatic breast cancer
and primary ovarian carcinoma. Metastatic breast cancer
assessment requires whole body CT-scan, bone scan, and
CA 15-3 measurement. Primary ovarian carcinoma
assessment requires extensive intra-abdominal explora-
tion and CA-125 measurement. Moreover, the prognosis
of metastatic breast cancer and primary ovarian carci-
noma widely differs, with a median progression-free sur-
vival ranging from 20 to 40 months, and from 9 to 30
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months, respectively [1,2]. Most importantly, therapeutic
options are very different. Usual therapies for advanced
breast cancer may combine or alternate hormonotherapy,
chemotherapy regimens, and targeted therapies accord-
ing to the tumor profile. Conversely, medical therapeutic
options for ovarian cancer are scarce, based on paclitaxel-
carboplatin combination. Other drugs have been shown
to provide minor benefits to the patients, and targeted
therapies are only entering early clinical trials.
Surgery is required to provide a thorough exploration
of the abdominal cavity, to remove malignant ovarian
lesions, to obtain a diagnosis, which is crucial for progno-
sis, and to plan adequate treatment [3]. In surgical series,
ovarian metastases from other primary cancers represent
5% to 20% of all ovarian cancers [3-5]. Metastatic lesions
to the ovaries are more commonly seen from primary
colon cancer, appendiceal, and breast carcinomas. How-
ever, there are few clinical or pathological features that
make possible to arrive at a differential diagnosis between
primary and secondary tumors [6,7].
BRCA1 and BRCA2 mutation carriers have an
increased risk of primary breast and ovarian tumors [8],
whereas patients with an infiltrating lobular carcinoma
(ILC) of the breast are more likely to develop secondary
ovarian metastases [9,10]. To date, pathological examina-
tion remains the cornerstone of the differential diagnosis
between primary ovarian tumor and ovarian metastases.
In case of metastatic lesions, the involvement of ovaries is
more often bilateral, and associated with ascites [3-5]. In
those tumors, the pathological feature is more often a
stromal rather than a serous invasion, suggesting a meta-
static diffusion through blood and lymphatic vessels [5].
In that case, the differential diagnosis is of paramount
importance. Several approaches have been developed to
discriminate between primary and secondary ovarian
cancers. Among them, immunohistochemistry (IHC) has
evaluated diagnostic markers, presumably able to support
the diagnosis, such as PAX8, a transcription factor for
organogenesis of Müllerian system, or Wilms tumor sup-
pressor gene (WT1) whose expression is regulated by
PAX8 [11,12]. However, only limited series, without vali-
dation data, have been reported so far. We speculate that
genomic analysis may represent an alternative approach,
which could also add some robustness to PAX8 IHC data.
To our knowledge, only one study has evaluated high
throughput genomic analyses to refine the diagnosis of
ovarian lesions following an adenocarcinoma of the
endometrium [13]. In a series of nine patients, using 19 k
comparative genomic hybridization (CGH) arrays, the
authors established that, in three cases out of nine for
which the pathological diagnosis was equivocal, the
genomic analyses were able to provide a clear diagnosis.
In this series, no transcriptomic data were reported.
In the present work, we proposed to develop genomic
and transcriptomic approaches to discriminate between
primary and secondary ovarian tumors after breast can-
cer when the pathological diagnosis was equivocal. For
this purpose, we characterized genomic and transcrip-
tomic profiles in paired breast and ovarian tumors diag-
nosed in a same patient, and compared genomic data
with clinical and pathological characteristics.
Methods
Clinical cases and data
Sixteen patients who had developed an infiltrating breast
carcinoma and a subsequent ovarian tumor, and for
whom frozen tissues were available for both tumors were
i n c l u d e d  i n  t h e  s t u d y .  B r e a s t  t u m o r s  w e r e  c l a s s i f i e d
according to the American Joint Committee on Cancer
(AJCC)/Union Internationale Contre le Cancer (UICC)
staging system and usual pathological parameters [14].
Ovarian tumors were classified according to the Fédérati-
on Internationale de Gynécologie Obstétrique (FIGO)
staging system.
Information about surgical and systemic treatments,
and the occurrence of other metastatic sites were col-
lected. The clinical data were reviewed by two medical
oncologists (PHC, LM). Pathological data were blindly
reviewed by two pathologists (NW, XSG), and, in case of
discrepancy, a consensus was achieved. To ensure an
independent data extraction, all procedures were con-
ducted separately by reviewers, and samples were ana-
lyzed without knowledge of their supposed status (i.e.
primary tumor, or metastasis).
This study was approved by the Institutional Review
Board and Ethics committee. Patients were informed that
their biological samples could be used for research pur-
poses and that they had the right to refuse if they so
wished.
Immunohistochemical analysis
Immunohistochemical analysis was performed on forma-
lin-fixed paraffin-embedded tissue sections (depth: 3
μm). The samples were deparaffinized and pretreated in
EDTA buffer at pH 9 (40 minutes at 97°C), and then
hydrated in PBS solution for 5 minutes. Then, the rabbit
polyclonal anti-PAX8 antibody (Protein Tech Group Inc.,
Chicago, IL, USA) was applied (dilution: 1/200), and sam-
ples were incubated overnight at 4°C. The endogenous
peroxidase activity was blocked with hydrogen peroxide.
A second antibody directed against the primary anti-
PAX8 antibody and coupled with a peroxidase polymer
Envision+ (Dako, Trappes, France) was applied for 30
minutes. Then, the peroxidase was revealed during a 10-
minute incubation with a di-aminobenzidine solution
(DAB Dako K3468). Finally, samples were counterstainedMeyniel et al. BMC Cancer 2010, 10:222
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with haematoxylin (2 minutes), and mounted with per-
manent media.
DNA and RNA extraction and preparation for microarray 
experiment
Tumor DNA and RNA were provided by the Biological
Resource Center of the Institut Curie. Prior to DNA and
RNA isolation, a tissue section of tumor fragments was
performed and stained with hematoxylin and eosin to
evaluate tumor cellularity. All analyzed tumors had more
than 50% of tumoral cells on the tissue section. The DNA
was extracted from frozen tumor samples using a stan-
dard phenol/chloroform procedure. The total RNA was
isolated using TRIzol reagent (Invitrogen, Cergy-Pon-
toise, France) in accordance with the manufacturers'
instructions. The concentration of RNA was measured by
absorbance at 260 nm. The quality of each RNA sample
was determined with Agilent 2100 bioanalyzer. RNAs
were processed on chips only if the following criteria
were fulfilled: RIN (a measure of RNA quality) ≥ 7.6,
(28S/18S) ≥ 1.8, (260 nm/230 nm) ≥ 1.8, and (260 nm/280
nm) ≥ 1.8. Targets were prepared according to Affymetrix
(Affymetrix Inc., Santa Clara, CA, USA) One Cycle Syn-
thesis protocol, starting from 2 μg of total RNA. Targets
were hybridized to GeneChip®  Human Genome U133
plus 2.0 Arrays if yield and size of targets were reached.
Twenty micrograms of complementary RNA, with a spe-
cific size distribution were used to hybridize GeneChip®
Human Genome U133 plus 2.0 Array.
Regarding DNA, the quality was assessed on agarose
gel, if a smear was observed instead of a band, the sample
was discarded. A 250-ng genomic DNA was used to gen-
erate targets according to the GeneChip® Mapping 50 K
Xba protocol or Genome-Wide Human SNP Array 6.0
protocol. Targets were prepared if 45 μg of amplified
DNA were available and if their size was between 250 and
2,000 bp, and hybridized according to manufacturer's
recommendations.
50 k SNP Array and SNP6.0 Array data analysis
Intensity signals data from Genechip® Human Mapping
50 K Xba Array or Genome-Wide Human SNP Array 6.0
were normalized and analyzed using ITALICS (ITerative
and Alternative normaLIzation and Copy number calling
for affymetrix Single nucleotide polymorphism [SNP]
arrays) algorithm [15] or Partek Genomic Suite (Partek
Inc., St Louis, MO, USA), respectively. The detection and
determination of genomics events (gains, losses, amplifi-
cations and breakpoints) was performed using GLAD
(Gain and Loss Analysis of DNA) software [16] for
GeneChip®  Human Mapping 50 K Xba Array, and
Genomic Segmentation algorithm of Partek Genomic
Suite for Genome-Wide Human SNP Array 6.0. Single
nucleotide polymorphisms with smoothing value lower
and greater than 2 ± 0.28 were considered as loss and
gain, respectively. The profiles were visualized with the
VAMP software [17] or Partek Genomic Suite.
Gene expression data analysis
A series of 89 ovarian primary tumors and 36 ovarian
metastases from breast cancer with a clear pathological
diagnosis was used to establish a reference hierarchical
tree. All these samples were provided by the Resource
Biological Center of the Institut Curie and the chips were
processed and hybridized in our laboratory (Department
of Translational research). The dataset is publicly avail-
able on GEO http://www.ncbi.nlm.nih.gov/geo/ under
accession number GSE20565. RNAs were prepared
according to the manufacturer's instructions, and were
hybridized onto Affymetrix GeneChip® Human Genome
U133 plus 2.0 Arrays. Transcriptomic data were normal-
ized with gc-Robust Multi-array Average (gcRMA) algo-
rithm [18], using Partek Genomic Suite (Partek Inc., St
Louis, MO, USA). Unsupervised hierarchical clustering
of tumor samples was done using Partek Genomic Suite
software with standard Pearson's correlation as similarity
measure, and Ward's method as linkage criteria. The IQR
(a measure of the dispersion of each probe set intensity
value across all samples) was set in order to have 2 000
probe sets. First, the clustering was performed on this set
of reference samples (89 primary tumors and 36 ovarian
metastases), then the 16 ovarian samples with ambiguous
diagnosis were introduced in the dataset and the cluster-
ing was performed.
Clustering
Validation of the reference hierarchical tree was per-
formed using R environment and the clusterStab package
[19]. This package assessed the number of reliable clus-
ters and the stability of the hierarchical clustering with a
re-sampling approach whereby randomly selected sub-
sets of samples (70% each round) are repeatedly clus-
tered. The extent of similarity between the resulting
clusters was examined and measured by the Jaccard coef-
ficient ranging from zero (no similarity) to one (identical
clustering). We used this strategy for a number of clusters
ranging from 2 to 8, and we compared the results of Jac-
card distribution. Enrichment of values equal or close to
one indicated adequate choices of metric, agglomeration
method and number of clusters. The algorithm was run
with the commonly used metrics (Euclidean and Pearson
correlation), and the commonly used agglomeration
methods (average and Ward's method). The script of the
function was adapted in order to use the Pearson correla-
tion coefficient as metric (not implemented in the Bio-
conductor package). We used the Hmisc  package from
Bioconductor to calculate this correlation between sam-
ples.Meyniel et al. BMC Cancer 2010, 10:222
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The use of clusterStab package showed that the best
reliability of the number of clusters was detected when
using Pearson correlation coefficient as metric, Ward's
method as agglomeration method, and k = 2 clusters (Fig-
ure 1).
Results
Patient and tumor characteristics
The main characteristics of the sixteen patients and their
tumors are summarized in Table 1. The median age at
diagnosis of breast cancer was 48 years (range, 32 to 69
years), and at diagnosis of ovarian tumor was 54 years
(range, 38 to 71 years). The median time interval between
breast cancer and ovarian tumor diagnosis was 73
months (range, 0 to 150 months). One patient had an
ipsilateral breast relapse contemporaneous to the ovarian
tumor (case #2). All patients had a breast surgery plus
axillary dissection. Only two patients did not receive any
systemic therapy. Other patients received a systemic
treatment consisting of adjuvant chemotherapy, tamox-
ifen alone or chemoendocrine therapy according to insti-
tutional guidelines. All patients were irradiated according
to our institutional guidelines. At a median follow-up of
39 months after the diagnosis of ovarian tumor (range, 1
to 87 months), five patients were still alive, among whom
four had no evidence of disease. The median overall sur-
vival from breast cancer diagnosis was 78 months, and 29
months from ovarian tumor diagnosis.
The pathological features of breast and ovarian tumors
are presented in Table 2. For breast tumors, the expres-
sion of HER2 was assessed (data not shown) as negative
in five patients, and was not available for the eleven
remaining patients. HER2 is a marker of aggressiveness,
the overexpression of HER2 gene increases the cellular
growth and metastatic potentialities. For cases number 6,
11, 15 and 16, the clinical and pathological analyses were
not able to draw a definite conclusion regarding the ovar-
ian tumor diagnosis (Table 3) due to the unspecific clini-
cal presentation (i.e.: ovarian carcinoma) or pathological
presentation (poorly differentiated carcinoma which
could be compatible with either primary or secondary
ovarian tumor). Noteworthy, three of these four patients
developed previously a non-lobular breast carcinoma
(infiltrating ductal carcinoma in two, undifferentiated in
one). No anti-PAX8 staining was observed in primary
breast carcinoma (data not shown). For the sixteen ovar-
ian tumors, PAX8 was deemed positive in six cases, and
negative in ten cases. Based on clinical and pathological
characteristics, two patients were treated as metastatic
breast cancer, and two as primary ovarian cancer.
SNP array analysis
In four cases out of sixteen ovarian tumors, the patholog-
ical diagnosis was uncertain (Table 3). The comparison of
mammary and ovarian genomic profiles was first estab-
lished in the twelve available pairs with a clear diagnosis.
Figure 1 Distributions of Jaccard coefficients, for a number of clusters ranging from k = 2 to k = 8, derived from 100 independent random 
samplings of tumors. Distributions were presented only if Pearson correlation coefficient and Ward's method were used. The proportion of samples 
used for re-sampling was 0.7. For k = 2 clusters, the largest proportion of values near one indicated that tumors set up two stable clusters.Meyniel et al. BMC Cancer 2010, 10:222
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Table 1: Demographics, treatment, characteristics of breast and ovarian tumors, and disease outcome of the sixteen 
patients
Breast tumor Ovarian tumor
Case # BRCA 
status
Age at 
diagnosis
Stage Local 
treatment
Systemic 
treatment
Age at 
diagnosis
Time interval 
from BC (months)
FIGO 
stage
Metastatic site Outcome
1N D 4 5I I IM C T - T 4 8 3 4 I V L i v e r D O D
2 ND 48 III M CT 48 73* IV Liver DOD
3 ND 45 III BCS CT-T 57 150 IV Bone, liver DOD
4N D 5 9IB C S N o 7 0 1 3 0 I V P e r i t o n e a l  
carcinomatosis, 
axillary LN
DOD
5 ND 57 III M T 58 20 IIIc NA DOD
6 ND 49 III M CT-T 52 33 IIIc NA DOD
7B R C A 2  m 6 6 I B C S C T 6 7 1 9 I c N A N E D
8B R C A 1  w t ,  
BRCA2 uk
46 III BCS CT-T 46 0 IIa NA DOD
9 ND 34 III M CT-T 45 133 IV Peritoneal 
carcinomatosis, 
supraclavicular 
LN, brain
SD
10 ND 47 III M T 54 83 IIIc NA NED
11 BRCA1 m 69 III M CT 71 24 IIa NA DOD
12 Familial 
history ¤
47 III M CT-T 54 79 IIIc NA DOD
13 ND 50 I BCS No 57 87 IIc NA NED
14 ND 57 II BCS T 64 82 IIc NA NED
15 BRCA1 wt, 
BRCA2 wt
32 III M CT 38 74 IV Pleura DOD
16 ND 48 II BCS CT 49 18 IIIc NA DOD
BRCA: BReast CAncer gene, ND = not determined; m = mutation; wt = wild type; uk = unknown; M = mastectomy; BCS = breast-conserving surgery; 
CT = chemotherapy; T = tamoxifen; BC = breast cancer; LN = lymph nodes; NA = not applicable; DOD = died of disease; NED = no evidence of 
disease; SD = stable disease.
* Patient who developed simultaneously ipsilateral breast cancer relapse and ovarian tumor.
¤ Her mother had a c.669A > G/Gln147GIN variation in the BRCA2 gene.
In the subset of seven metastatic samples, one array
was not usable for analysis (signal intensity too noisy on
the chip). Among the six remaining samples, similar
genetic events were found in mammary and ovarian
tumors. The alterations found in breast samples were
observed in ovarian samples, whereas some additional
alterations were observed in the ovarian samples as visu-
ally depicted in Figure 2. Moreover, the breakpoints
detected in the mammary tumor were also found at the
same position in the ovarian sample. Additional break-
points were also found in this subset of ovarian tumors.
These observations led to the conclusions that these six
ovarian tumors were metastases of the primary breast
cancer.
In the other subset of five samples considered as pri-
mary ovarian carcinoma, no overlap of genomic altera-
tions was found between mammary and ovarian samples
(Figure 3). As well, no common position for breakpoints
was observed, thus confirming the primary status of the
ovarian tumors (Table 3).
Then, molecular diagnosis was performed on the four
ambiguous tumors. Two of them were classified as metas-
tases from breast cancer as similar genetic events were
observed in the primary tumor and its ovarian counter-
part (see Additional Files 1 and 2). The two remaining
tumors were classified as primary tumors as their genetic
profiles were strikingly different from those of the origi-
nal breast tumors (see Table 3 and Additional Files 3 and
4).Meyniel et al. BMC Cancer 2010, 10:222
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Transcriptomic analysis
Fifteen out of sixteen gene expression profiles of ovarian
tumors were obtained. These tumors were included in a
set of samples including well-identified primary ovarian
tumors (n = 89), and ovarian metastases (n = 36). All the
samples were processed, normalized, and clusterized as
described above. Therefore, a hierarchical tree with two
main branches was obtained: the first branch gathered all
metastatic samples, and the second branch contained all
primary tumors but one (Figure 4). The reference hierar-
chical tree obtained with the 125 reference tumors was
not modified when the fifteen studied tumors were
added. Two main branches were repeatedly generated
with the raising of the tree from 125 to 140 tumors. The
fifteen ovarian tumors of the core subset all segregated
accordingly to the pathological diagnosis and their
genomic profiles (Figure 4, Table 3). The tumor #1, with
no SNP array data, clearly segregated with metastatic
tumors.
Discussion
So far, no definitive molecular profiling of ovarian cancer
has been published. Molecular characterization is only
based on grade, histo-pathological features and some key
genes alterations. As well, no high-throughput molecular
data on ovarian metastasis have been reported. This
study is the first to use a comprehensive genomic analysis
to discriminate primary ovarian carcinomas and meta-
static ovarian lesions from breast cancer. A similar
approach was evaluated to distinguish primary from sec-
ondary ovarian tumors after adenocarcinoma of the
endometrium [13]. Using a 19 K CGH array, four cases
out of nine remained undetermined. In our data set, the
pathological status of ovarian lesions was well established
in twelve cases. The blind test of these pairs for SNP and
transcriptomic analyses was in agreement with the patho-
logical analysis (Table 3). In the four lesions with an
ambiguous pathological diagnosis, SNP and transcrip-
tomic analyses permitted to clearly discriminate primary
tumor and metastatic disease. This is also the first time
that both transcriptomic and genomic analyses were per-
formed, demonstrating a complete overlap of results with
these two kinds of analyses.
The purpose of the present work was not to provide a
genomic signature, but to give a diagnosis allowing a
treatment decision. Conversely to the study of ovarian
tumors after adenocarcinoma of the endometrium using
low-density 19 k BAC arrays [13], we used high-density
50 K SNP arrays, showing major chromosomal alterations
in all tumors. This method allowed interpretation and
Table 2: Pathological features of breast and ovarian tumors
Histology Grade ER PgR
Case # Breast Ovary Breast Ovary Breast Ovary Breast Ovary
1 ILC Lobular carcinoma I ND + + + ND
2 IDC, then ILC* Lobular carcinoma III, then II ND + ND + ND
3 ILC Lobular carcinoma I ND + + + ND
4 ILC Lobular carcinoma ND ND + + + -
5 ILC Lobular carcinoma III ND + ND + ND
6 ILC Lobular carcinoma II ND + ND - ND
7 IDC Serous papillary III III - ND - ND
8 IDC Serous papillary III II + - + +
9 IDC Poorly differentiated ADK III ND + ND + ND
10 IDC and ILC (mixed) Serous papillary III III + - + -
11 IDC Poorly differentiated ADK III II - + - +
12 ILC Lobular carci n o m a I I I N D +++N D
13 IDC Serous papillary II III + ND + ND
14 IDC Clear cell II II + ND - ND
15 IDC Poorly differentiated ADK II ND + ND + ND
16 Undifferentiated Serous papillary III III - + - +
ND = not determined; ILC = infiltrating lobular carcinoma; IDC = infiltrating ductal carcinoma; ADK = adenocarcinoma; ER = estrogen receptor; 
PgR = progesterone receptor.
* Initial breast cancer was an IDC, and local relapse was an ILC (subject of genomic analysis).Meyniel et al. BMC Cancer 2010, 10:222
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comparison of the genomic profiles within the fifteen
available pairs of breast and ovarian tumors. When most
of genomic alterations found in primary breast tumors
were included in the ovarian counterpart, a genomic
diagnosis of metastases was proposed and then con-
firmed by the comparison with the histopathological
diagnosis. A previous experience of CGH in metastatic
breast cancer has been reported, comparing primary
tumor with lymph node metastases, distant metastases or
local recurrences in sixteen patients [20]. Genomic pro-
files comparison showed that additional aberrations were
detected in the lymph nodes or distant metastases when
compared to the primary tumors. These findings suggest
that progression from primary breast cancer to metasta-
sis may be associated with the acquisition of further
genetic changes. Overall, in the present series, we con-
firmed these findings and proposed the use of SNP array
Table 3: Comparison between pathological analyses, CGH, transcriptomic profiles, and immunohistochemistry profiles
Case # Pathological analysis Genomic analysis Transcriptomic analysis PAX8 IHC
1 Metastasis ND Metastasis Negative
2 Metastasis Metastasis Metastasis Negative
3 Metastasis Metastasis Metastasis Negative
4 Metastasis Metastasis Metastasis Negative
5 Metastasis Metastasis Metastasis Negative
6 Plausible metastasis Metastasis Metastasis Negative
7 Primary tumor Primary tumor Primary tumor Positive
8 Primary tumor Primary tumor Primary tumor Positive
9 Metastasis Metastasis Metastasis Negative
10 Primary tumor Primary tumor Primary tumor Positive
11 Plausible primary tumor Primary tumor Primary tumor Positive
12 Metastasis Metastasis Metastasis Negative
13 Primary tumor Primary tumor Primary tumor Positive
14 Primary tumor Primary tumor ND Negative
15 Plausible metastasis Metastasis Metastasis Negative
16 Plausible primary tumor Primary tumor Primary tumor Positive
PAX8: Paired Box 8 gene; ND = not determined; IHC = immunohistochemistry.
Figure 2 (A) Genomic profile of the breast/ovary sample pair #9. 
In the zoomed area, similar altered areas and breakpoint positions (red 
vertical lines) between mammary and ovarian tumors were detected. 
Yellow = normal; red = gain; green = loss; blue = amplification. X axis: 
all chromosomes, Y axis: SNP copy number. (B) Histological sections 
of breast (upper) and ovarian (lower) tumors
Figure 3 (A) Genomic profile of the breast/ovary sample pair #8. 
In the zoomed area, no similarities for altered areas and breakpoint po-
sitions (red vertical lines) between mammary and ovarian tumors were 
detected. Yellow = normal; red = gain; green = loss; blue = amplifica-
tion. X axis: all chromosomes, Y axis: SNP copy number. (B) Histologi-
cal sections of breast (upper) and ovarian (lower) tumorsMeyniel et al. BMC Cancer 2010, 10:222
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technology to provide a definite diagnosis in case of
equivocal ovarian lesions.
Furthermore, the present study highlighted that the
transcriptomic analysis was always in concordance with
the pathological diagnosis in the reference set of well-
identified 125 tumors, excepted for one case considered
as a metastasis, but clustering with primary tumors (Fig-
ure 4). Both analyses (genomic and transcriptomic) were
possible in fourteen pairs of tumors, and results were
always identical (Table 3). Given the robustness of our
reference tree, we have therefore established a dataset of
reference that is now available for future research and
diagnostic purposes. The main interest of this method is
to have at one's disposal a test that does not require the
primary tumor to give a diagnosis. Indeed, other authors
have reported a similar approach in particular with Carci-
nomas of Unknown Primary (CUP) [21], suggesting that
expression data may help in elucidating the histogenetic
origin of metastatic tissue. The future directions might be
t o  e n r i c h  o u r  d a t a s e t  o f  t u m o r s  l i k e l y  t o  g i v e  o v a r i a n
metastases, such as gastric or colorectal carcinomas.
The use of WT1 in IHC analysis seems not to be appro-
priate to discriminate between primary and secondary
tumors. A recent study [22] showed that WT1 is rather
dedicated to distinguish between serous and endometri-
oids ovarian carcinomas. So, in our study, we preferred to
use PAX8 staining instead of WT1 staining for the dis-
tinction of primary and secondary lesions.
Interestingly, PAX8 IHC status was in concordance
with genomic results in the present model of primary
ovarian tumors compared to ovarian metastases from
breast cancer, except for one patient who had a clear-cell
carcinoma. PAX8 is usually highly, but not always,
expressed in serous-papillary (96,4%), endometrioid
(88,9%) or clear-cell carcinoma (100%) [11]. In the series
of these authors, PAX8 staining was positive for all the
clear-cell carcinoma (10/10), so they concluded that
PAX8 was particularly useful for the diagnosis of this his-
totype. But the only one sample which is not stained in
our collection is a clear-cell ovarian carcinoma. More-
over, no definite nor consensual criteria for PAX8 IHC
positivity has been defined so far, yielding some concern
about the reproducibility of their technique. To our opin-
ion, PAX8 IHC does not provide a totally robust result
concerning the status of ovarian tumors. In the present
series, genomic analyses yielded a definite diagnosis in all
cases. In another study concerning mouse model of
human ovarian endometrioid adenocarcinoma [23], the
authors performed IHC and sequence analysis, in paral-
lel, on some genes implicated in the pathology. For
CTNNB1 gene, the results were totally concordant
between IHC and sequence analyses. But for other genes,
like PTEN and TP53, there were some discrepancies. For
example, 12 samples were found to be mutated with IHC
for PTEN whereas when the authors examined the
sequence, mutations were found only in 6 samples. In this
case, they detected 6 false positives with IHC analysis.
Also, when they analyzed TP53 mutations, they detected
3 false positives and 2 false negatives between IHC and
sequence analyses. These results demonstrate that
genomic tools are more appropriate to determine defini-
tively the mutational status of genes.
Figure 4 Hierarchical clustering. Pearson's correlation coefficient 
and Ward's method were used. In red are the ovarian metastases sam-
ples, and in blue the ovarian primary tumors. Red and blue arrows lo-
calized the ovarian metastases and primary tumor samples, 
respectively, among the 16 cases included in this studyMeyniel et al. BMC Cancer 2010, 10:222
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Conclusions
We established the robustness of SNP and transcriptomic
analysis to discriminate primary ovarian tumors and
ovarian metastases after primary breast cancer. Notewor-
thy, all genomic analyses were blindly compared to clini-
cal and pathological characteristics. An algorithm of
diagnosis could be considered in the light of these results
(Figure 5). The first step remains the pathological analy-
sis. If the primary tumor is not available, which repre-
sents the majority of cases, a transcriptomic analysis may
be performed. If the primary tumor is available, the SNP
array is the preferential test. Of course, these results
require further analyses and comparison with other bio-
markers.
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